Overview of hypertension treatment
This online CPD accompanies an article published in The Pharmaceutical Journal earlier this month on monitoring hypertension (2 October 2010, pp375–8).
Jon Waterfield, summarises the current recommendations for the treatment of hypertension and explains the rationale behind them
In 2006, the British Hypertension Society collaborated with the National Institute for Health and Clinical Excellence to produce updated guidance on the treatment of hypertension, based on the appraisal of data from studies published since July 2004.
The guidance recommended a major change in that beta-blockers were no longer recommended as routine initial therapy because in head-to-head trials they were less effective than a comparator drugs at reducing major cardiovascular events, particularly stroke.
Instead, calcium-channel blockers, thiazide-type diuretics or angiotensin-converting enzyme inhibitors were recommended as first-line treatment.
To read the full article download the attached PDF (910K)
Jon Waterfield, MSc, MRPharmS, is a principal lecturer in pharmacy practice at Leicester School of Pharmacy, De Montfort University
Case studies, patient decision aids and data-focused commentary are available on the “hypertension floor” of the National Prescribing Centre’s NPCi website.
Citation: The Pharmaceutical JournalURI: 11030111
Recommended from Pharmaceutical Press